A study showed that intermittent treatments and off dosing schedules may double the time of melanoma response to vemurafenib.74 However, intermittent treatment strategies are usually difficult to design as drug resistance may be complex and come from multiple mechanisms other than TCP.236,237 Combination therapies have also been applied to target parallel activation of key signaling pathways such as Hippo/yes-associated protein (YAP), PI3K, and EGFR,238,239 resulting in a significant decrease in the number of residual tumor cells. Here, EGFR is linked to neoplasm.